Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection
Top Cited Papers
Open Access
- 15 February 2011
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (4), 447-456
- https://doi.org/10.1093/cid/ciq106
Abstract
Background. Experience from treating patients with Spanish influenza and influenza A(H5N1) suggested that convalescent plasma therapy might be beneficial. However, its efficacy in patients with severe pandemic influenza A(H1N1) 2009 virus (H1N1 2009) infection remained unknown. Methods. During the period from 1 September 2009 through 30 June 2010, we conducted a prospective cohort study by recruiting patients aged ≥18 years with severe H1N1 2009 infection requiring intensive care. Patients were offered treatment with convalescent plasma with a neutralizing antibody titer of ≥1:160, harvested by apheresis from patients recovering from H1N1 2009 infection. Clinical outcome was compared with that of patients who declined plasma treatment as the untreated controls. Results. Ninety-three patients with severe H1N1 2009 infection requiring intensive care were recruited. Twenty patients (21.5%) received plasma treatment. The treatment and control groups were matched by age, sex, and disease severity scores. Mortality in the treatment group was significantly lower than in the nontreatment group (20.0% vs 54.8%; P = .01). Multivariate analysis showed that plasma treatment reduced mortality (odds ratio [OR], .20; 95% confidence interval [CI], .06-.69; P = .011), whereas complication of acute renal failure was independently associated with death (OR, 3.79; 95% CI, 1.15-12.4; P = .028). Subgroup analysis of 44 patients with serial respiratory tract viral load and cytokine level demonstrated that plasma treatment was associated with significantly lower day 3, 5, and 7 viral load, compared with the control group (P < .05). The corresponding temporal levels of interleukin 6, interleukin 10, and tumor necrosis factor α (P < .05) were also lower in the treatment group. Conclusions. Treatment of severe H1N1 2009 infection with convalescent plasma reduced respiratory tract viral load, serum cytokine response, and mortality.Keywords
This publication has 39 references indexed in Scilit:
- The Infection Attack Rate and Severity of 2009 Pandemic H1N1 Influenza in Hong KongClinical Infectious Diseases, 2010
- Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion GlycoproteinJournal of Virology, 2010
- Differences in the Epidemiological Characteristics and Clinical Outcomes of Pandemic (H1N1) 2009 Influenza, Compared with Seasonal InfluenzaInfection Control & Hospital Epidemiology, 2010
- Rapid Selection of Oseltamivir‐ and Peramivir‐Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised HostsClinical Infectious Diseases, 2010
- Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemicProceedings of the National Academy of Sciences, 2010
- Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, ChinaEmerging Infectious Diseases, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress SyndromeJAMA, 2009
- Confirmation of the First Hong Kong Case of Human Infection by Novel Swine Origin Influenza A (H1N1) Virus Diagnosed Using Ultrarapid, Real-Time Reverse Transcriptase PCRJournal of Clinical Microbiology, 2009
- Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 InfluenzaPLoS Medicine, 2007